10th week of 2013 patent applcation highlights part 35 |
Patent application number | Title | Published |
20130058883 | COMPOSITION FOR MAKING UP AND/OR CARING FOR KERATINOUS FIBERS AND PRESENTING IMPROVED STAYING-POWER PROPERTIES - A cosmetic composition for making up and/or caring for keratinous fibers. The composition includes at least: an oily phase formed at least of isododecane, and at least 4% by weight, relative to the total weight of the composition, of at least one oil of volatility that is less than that of isododecane; at least 9% by weight, relative to the total weight of the composition, of active material including at least one liposoluble film-forming polymer; and a particulate phase containing at least one compound selected from pigments, nacres, fillers, and waxes. | 2013-03-07 |
20130058884 | HERBAL OIL WHICH IS USED IN HAIR CARE AND IN MASSAGE AND WHICH IS USED IN TREATMENT OF HAIR LOSS, HAIRLESSNESS, AND BURNS - A compound which is obtained by mixing olive oil with natural vegetables and their essentials which are used in hair care and which prevents hair loss, removes deformation and allows healthy hairs to regrow if hair has been lost, allows new hairs coming out when it is applied where hairlessness has occurred, and which, also allow pains from sunburn, skin burn, and fire burn stopping and removing completely sears from such burns. The compound may also be used as massage oil. | 2013-03-07 |
20130058885 | Personal Care Compositions Comprising Squash or Pumpkin Extract - Embodiments of the present invention relate to novel personal care compositions for cleaning and moisturizing the skin or hair comprising an extract of squash and/or pumpkin, a preservative and a cosmetic base. Other embodiments of the present invention relate to methods of making and methods of using the personal care compositions. | 2013-03-07 |
20130058886 | PERFUME COMPOSITIONS COMPRISING FUNCTIONAL PERFUME COMPONENTS - Perfume compositions having functional perfume components for aiding in perfume evaporation. The functional perfume components have a Kovat's index in the range of 900-1400 and an ODT of greater than about 1 ppb. In one embodiment, the functional perfume component may be present in an amount from at least about 10% by weight of the composition. In another embodiment, the composition containing a function perfume component is substantially free of a VOC. | 2013-03-07 |
20130058887 | ALDEHYDE-REMOVING COMPOSITION - An object of the present invention is to provide a composition for removing aldehyde. Specifically, the present invention relates to an aldehyde-removing composition comprising a microorganism belonging to the genus | 2013-03-07 |
20130058888 | Compositions Comprising Soil Adsorption Polymers For Reducing Particulates In The Air - Compositions comprising soil adsorption polymers for reducing particulates in the air are provided. | 2013-03-07 |
20130058889 | ANTIFOULING PAINT COMPOSITION, PRODUCTION METHOD OF ANTIFOULING PAINT FILM, AND ANTIFOULING PAINT FILM - The present invention provides an antifouling paint composition, by which a paint film can be formed using a small amount of an organic solvent, in which the strength and the self-abradability can be maintained for a long period, and by which a paint film having an excellent antifouling property can be formed. The antifouling paint composition according to the present invention contains an acrylic polymer (P), a radical polymerizable monomer (M) and an organic peroxide (O), wherein at least one of the acrylic polymer (P) and the radical polymerizable monomer (M) has a bivalent metal ester structure. | 2013-03-07 |
20130058890 | METHODS FOR CONTROLLING PESTS USING RNAi - The present invention concerns methods for controlling insect infestation via RNAi-mediated gene silencing, whereby the intact insect cell(s) are contacted with a double-stranded RNA from outside the insect cell(s) and whereby the double-stranded RNA is taken up by the intact insect cell(s). In one particular embodiment, the methods of the invention are used to alleviate plants from insect pests. Alternatively, the methods are used for treating and/or preventing insect infestation on a substrate or a subject in need of such treatment and/or prevention. Suitable insect target genes and fragments thereof, dsRNA constructs, recombinant constructs and compositions are disclosed. | 2013-03-07 |
20130058891 | Kexin-Derived Vaccines to Prevent or Treat Fungal Infections - A vaccine is disclosed that promotes CD4+ T cell-independent host defense mechanisms to defend against infection by fungi such as | 2013-03-07 |
20130058892 | PYRIMIDINYL INDOLE COMPOUNDS - The present invention provides pyrimidinyl indole compounds as novel kinase inhibitors for the treatment of cancer and inflammatory diseases. | 2013-03-07 |
20130058893 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof - Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided. | 2013-03-07 |
20130058894 | THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE - Disclosed are therapeutic protein-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 2013-03-07 |
20130058895 | High Pressure Treatment of Aggregated Interferons - Methods are provided using high pressure to treat aggregated interferons, to reduce the aggregate content of interferon material. In particular, recombinant human interferon-β may be so treated. Multiple strategies may be used in combination to make nonglycosylated IFN-β more amenable to high pressure treatment. When coupled with purification techniques, these strategies singly or in combination provide a low aggregate or substantially aggregate free, biologically active solution. In certain aspects, pharmaceutical compositions containing nonglycosylated interferon having less than about 5 weight percent of protein aggregation are provided. | 2013-03-07 |
20130058896 | COMPOSITIONS AND METHODS RELATED TO ANTI-FGF AGENTS - The invention relates to an isolated amino acid that can act as an antagonist to FGF signaling, comprising at least a portion of the FGF protein amino acid sequence, and including a mutation in either a) the integrin αvβ3 binding region of FGF-1; or b) the FGFR binding region of FGF-1. | 2013-03-07 |
20130058897 | HEXON ISOLATED FROM SIMIAN ADENOVIRUS SEROTYPE 19, HYPERVARIABLE REGION THEREOF AND CHIMERIC ADENOVIRUS USING THE SAME - Novel hexon isolated from simian adenovirus serotype 19 encoded in the polynucleotide defined as SEQ ID NO: 3, hepervariable region thereof, chimeric adenovirus comprising the same, and therapeutic use thereof provides a solution to the problem of safety and effective systemic treatment for developing gene therapeutic agents using adenovirus. | 2013-03-07 |
20130058898 | LACTIC ACID BACTERIUM-CONTAINING PREPARATION - The present invention provides very safe lactic acid bacteria and lactic acid bacteria preparations which are effective in prevention and therapy of allergies and/or in lowering of the blood neutral fat level. The present invention also provides pharmaceutical products and food or drink products which contain, as an active ingredient, a composition that contains cultured cells of the lactic acid bacterium | 2013-03-07 |
20130058899 | Cancer Therapy with a Parvovirus Combined with an HDAC Inhibitor - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) a histone deacetylase inhibitor (HDACI) and the use of said composition for treatment of cancer, e.g., brain tumor, cervical carcinoma, or pancreatic carcinoma. | 2013-03-07 |
20130058900 | Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells - The invention is concerned with producing differentiated cells, tissues and organs from pluripotent and mutlipotent cells. The methods of the invention are particularly useful for producing differentiated cells from pluripotent cells wherein communication between the cells of more than one embryonic germ layer or more than one organ system are required for development along a specific cell lineage. The invention methods are effected by in vivo or in vitro culturing of embryonic and developing or developed allogeneic or xenogeneic cells. | 2013-03-07 |
20130058901 | TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE - Disclosed are transplantable graft-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 2013-03-07 |
20130058902 | DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS - Disclosed are induced tolerogenic dendritic cells (itDCs) produced from dendritic cell subsets that possess a desired physiological characteristic, as well as related compositions and methods. | 2013-03-07 |
20130058903 | Stem-Cell Material and Method of Use - Provided herein are mesenchymal stem cells which have been modified by the introduction of polynucleotides encoding for a mammalian Cdk1 protein. These cells do not sense in culture and are non-tumorigenic thereby providing an ongoing source of cells as well as conditioned medium. The conditioned medium from these cells can be used for tissue repair. Also provided is a method of modifying mesenchymal stem cells which can be continuously propagated in culture and are non-tumorigenic. | 2013-03-07 |
20130058904 | Method and system for treatment of biological tissue - A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative. | 2013-03-07 |
20130058905 | Angiohematopoietic Progenitor Cells - A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a. | 2013-03-07 |
20130058906 | PROCESS, TUBE AND DEVICE FOR THE PREPARATION OF WOUND HEALANT COMPOSITION - The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof. | 2013-03-07 |
20130058907 | METHOD AND SYSTEM FOR THE PRODUCTION OF CELLS AND CELL PRODUCTS AND APPLICATIONS THEREOF - A cell culture system for the production of cells and cell derived products includes a reusable instrumentation base device incorporating hardware to support cell culture growth. A disposable cultureware module including a cell growth chamber is removably attachable to the instrumentation base device. The base device includes microprocessor control and a pump for circulating cell culture medium through the cell growth chamber. The cultureware module is removably attached to the instrumentation base device. Cells are introduced into the cell growth chamber and a source of medium is fluidly attached to the cultureware module. Operating parameters are programmed into the microprocessor control. The pump is operated to circulate the medium through the cell growth chamber to grow cells or cell products therein. The grown cells or cell products are harvested from the cell growth chamber and the cultureware module is then disposed. | 2013-03-07 |
20130058908 | HIGH AFFINITY NY-ESO T CELL RECEPTORS - The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC SEQ ID NO:126 peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K | 2013-03-07 |
20130058909 | METHODS OF TREATMENT USING EX VIVO EXPANSION OF CORD BLOOD T CELLS - Provided are methods of enhancing ex vivo proliferation of a T cell population, the methods comprising contacting the T cell population with IL-7 and anti-CD3/CD28 antibody to activate and expand the T cell population. Further provided are methods of generating an antigen-specific cytotoxic T cell population comprising priming a CD3/CD28-expanded T cell population against an antigen (e.g., a cancer cell) in the presence of at least one of IL-7, IL-12, and IL-15, or a combination thereof. Further provided are methods of treating T cell lymphopenia in a subject, comprising administering a CD3/CD28-expanded T cell population to the subject. | 2013-03-07 |
20130058910 | DECONTAMINATION OF CHEMICAL AND BIOLOGICAL AGENTS - A system includes at least one oxidase. at least one haloperoxidase; at least a first polymer including groups exhibiting nucleophilic activity for organophosphorus compounds, and a source of halide ions to serve as a substrate for haloperoxidase-catalyzed generation of halogens. The source of halide ions may, for example, include salt crystals or a salt in an extended release system. In a number of embodiments, the first polymer includes halide ions. | 2013-03-07 |
20130058911 | REDUCING AGENT FROM MICROORGANISM BELONGING TO GENUS BACILLUS AND APPLICATION FOR SAME - The present invention is intended to provide a reducing agent effective for color development of meat and uses therefor. The present invention provides a reducing agent containing a heme reductase derived from a microorganism belonging to the genus | 2013-03-07 |
20130058912 | Therapeutic Charge Engineered Variants of Lysozyme and Methods for Using Same to Treat Infections - The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrobial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug. | 2013-03-07 |
20130058913 | Lactase Formulations - A particulate composition comprising a plurality of particles comprising lactase and a protective material are provided. The particles have a size that is not perceptible or is minimally perceptible on the human tongue. The particulate composition can be made by a method that comprises the steps of providing a lactase, providing a protective material, and forming a particulate composition comprising a plurality of particles comprising the lactase and the protective material in a size that is not perceptible or barely perceptible on the human tongue. The particulate composition can be used by applying the lactase composition to a food article or by using the lactase composition in the course of consuming the food article. | 2013-03-07 |
20130058914 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 2013-03-07 |
20130058915 | METHODS AND COMPOSITIONS FOR TREATMENT OF ANGELMAN SYNDROME AND AUTISM SPECTRUM DISORDERS - Methods for the treatment of Angelman Syndrome autism spectrum disorders are provided. The methods comprise administrating to a subject an agent that increases the expression of or increases activity of, ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) at neuronal synapses. | 2013-03-07 |
20130058916 | PROANGIOGENIC COMPOSITIONS, METHOD FOR PREPARING SAME, AND USES THEREOF - The disclosure relates to an electrodynamic-transducer magnetic motor device ( | 2013-03-07 |
20130058917 | ANTIBODY COMPOSITION OBTAINED BY FRACTIONATION OF PLASMA IMMUNOGLOBULINS AFFINITY CHROMATOGRAPHY ON A SAMBUCUS NIGRA AFFINITY COLUMN - The invention relates to populations of antibodies obtainable by fractionation of plasma immunoglobulins, in particular plasma IgG, by affinity chromatography on a | 2013-03-07 |
20130058918 | ISOLATION AND USE OF A NEW TYPE OF GLIAL CELL WITH NEUROTOXIC POTENTIAL - The present invention provides for an isolated population of aberrant astrocytes, methods of isolating the aberrant astrocytes, methods of diagnosing neurodegenerative diseases, methods of drug screening using the aberrant astrocytes, and treatment methods targeting function, activity, and signaling associated with aberrant astrocytes. | 2013-03-07 |
20130058919 | Optimized Fc Variants and Methods for their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 2013-03-07 |
20130058920 | METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE - The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive. | 2013-03-07 |
20130058921 | USE OF AUTOLOGOUS EFFECTOR CELLS AND ANTIBODIES FOR TREATMENT OF MULTIPLE MYELOMA - The present disclosure provides methods for treating multiple myeloma using a combination of autologous expanded and activated NK cells from the patient and an antibody that targets an antigen on myeloma cells and/or an antibody that targets the KIR antigen on NK cells, wherein the antibodies elicit ADCC toward myeloma cells. The present disclosure provides methods for treating multiple myeloma using a combination of autologous NK cells and the anti-CS1 antibody elotuzumab. | 2013-03-07 |
20130058922 | PHARMACEUTICAL COMPOSITION CONTAINING CHOLINE - The invention relates to pharmaceutical compositions, in particular for intravenous administration, containing choline or pharmaceutically acceptable salts or analogues thereof. | 2013-03-07 |
20130058923 | BIOMOLECULAR INTERACTIONS AND INTERACTION PRODUCTS AS BIOMARKERS FOR DETECTION, DIAGNOSIS, PROGNOSIS AND PREDICTING THERAPEUTIC RESPONSES OF HUMAN DISEASES - Included in the disclosure is description of a method of determining a presence, and/or aggressiveness level, and/or response to therapy of a human disease in a subject. The method involves determining size of nanoparticles upon being exposed to a biological sample or a component of biological sample or pretreated biological sample from the subject to form an assay solution, wherein the average particle size of the assay solution is correlative to the presence, and/or aggressiveness level, and/or response to therapy of disease in said subject | 2013-03-07 |
20130058924 | HYPOXIA-RELATED GENE SIGNATURES FOR CANCER CLASSIFICATION - Biomarkers, particularly hypoxia-related genes, and methods using the biomarkers for molecular detection and classification of disease are provided. | 2013-03-07 |
20130058925 | EPITHELIAL BIOMARKERS FOR CANCER PROGNOSIS - Methods, systems and compositions for the prognosis and classification of cancer, especially bladder cancer, are provided. For example, in certain aspects methods for cancer prognosis using expression analysis of selected biomarkers such as miR-200 and TGFalpha are described. | 2013-03-07 |
20130058926 | METHOD FOR ALLEVIATING AND/OR PREVENTING SKIN REDDENING - A method of alleviating and/or preventing skin reddening for a subject in need thereof by means of inhibiting angiogenesis at the site of the reddened skin, is provided. | 2013-03-07 |
20130058927 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 2013-03-07 |
20130058928 | HAIR GROWTH METHODS USING FGFR3 EXTRACELLULAR DOMINS - The present invention relates to a method of promoting hair growth comprising administering a fibroblast growth factor receptor 3 (FGFR3) extracellular domain (ECD), including native FGFR3 ECDs, variants, fragments, and fusion molecules, to a subject in an amount sufficient to promote hair growth. | 2013-03-07 |
20130058929 | FUSION PROTEINS FOR INHIBITION AND DISSOLUTION OF COAGULATION OF THROMBI - Fusion proteins containing a ligand which specifically binds to a selected vascular bed linked to an anti-thrombotic molecule are provided. Also provided are methods for use of these fusion proteins to prevent coagulation, to dissolve blood clots and to protect against the risk of iatrogenic side effects including those arising from cancer therapy and specific vascular occluding agents. | 2013-03-07 |
20130058930 | SUBCUTANEOUS NEEDLE ASSISTED JET INJECTION ADMINISTRATION OF METHOTREXATE - The present application is directed, at least in part, to a method of treating an autoimmune disorder in a subject in need of treatment. In one exemplary embodiment, the method comprises introducing into the subcutaneous tissue of the subject, from a needle assisted jet injection device, a composition comprising methotrexate in a dose ranging from about 5 mg to about 50 mg, wherein the pharmacokinetic profile of said methotrexate, obtained following administration of the methotrexate by the needle assisted jet injection device, is substantially the same as the pharmacokinetic profile of the same dose of methotrexate when administered by an intramuscular injection or a subcutaneous injection. The present invention provides benefits and improvements, including an improved clinical utility, improved therapeutic efficacy, over conventional methods of administering methotrexate. | 2013-03-07 |
20130058931 | METHODS OF PREDICTING AND DECREASING THE RISK OF PREGNANCY LOSS - Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the absence or a non-detectable level of antibodies specifically binding to alpha2M is associated with a history of RPL and an increased risk of pregnancy loss. Also described are methods for identifying subjects at risk of pregnancy loss, selecting subjects for participation in a clinical study, and methods of decreasing the risk of pregnancy loss in a subject which include detecting the presence or absence of antibodies to one or more of trophoblast-derived ApoB-100, alpha2M, and fibronectin. Also provided are kits that contain ApoB-100, alpha2M, and fibronectin. | 2013-03-07 |
20130058932 | USE OF PKC-IOTA INHIBITORS FOR THE TREATMENT OF GLIOMA - The present invention pertains to use of PKC-iota inhibitors for treatment of glioma. In a specific embodiment, the treatment method comprises administering ICA-1 or a salt thereof to a subject with glioma. In another embodiment, the treatment method comprises contacting glioma cells with an effective amount of ICA-1 or a salt thereof. | 2013-03-07 |
20130058933 | MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR - The invention relates to monovalent ligands of the human CD28 receptor, which can selectively block the interaction between CD28 and B7 without activating the CD28 receptor. Said ligands can be used in particular in the production of immunosuppressant drugs, selectively blocking T lymphocyte activation phenomena involving the CD28 receptor. | 2013-03-07 |
20130058934 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES - The present disclosure relates to antibodies targeting LRP6 and compositions and methods of use thereof. | 2013-03-07 |
20130058935 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 7R - Antibodies that specifically bind to an epitope on the extracellular domain of TEM7R are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. The antibodies may be used in methods for treating tumors and for inhibiting angiogenesis in tumors. | 2013-03-07 |
20130058936 | BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE - The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2013-03-07 |
20130058937 | Bispecific antigen binding molecules - The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. | 2013-03-07 |
20130058938 | GNA11 MUTATIONS IN MELANOMA - The present invention provides methods of detecting mutations in a GNA11 gene in a melanocytic neoplasm for diagnostic and prognostic purposes. The invention further provides methods of treating such melanocytic neoplasm by modulating the activity of the mutated GNA11 gene. | 2013-03-07 |
20130058939 | TREATMENT OF NEUROLOGICAL OR NEURODEGENERATIVE DISORDERS - The invention relates to a protein or peptide consisting of a kringle protein or peptide and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates also to an isolated antibody of fragment thereof which binds to the N-terminal domain of the NMDA receptor subunit NR1 (anti-NR1 antibody), whereas binding of the antibody or the fragment thereof prevents the cleavage of the extracellular domain of the NR1 subunit, or the fragment and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates further to a pharmaceutical composition containing said kringle protein or peptide or anti-NR1 antibody. | 2013-03-07 |
20130058940 | Novel Gene And Protein Associated With Angiogenesis And Endothelial Cell Specific Apoptosis - This invention provides isolated nucleic acid and amino acid sequences encoding VG5Q, a novel angiogenic growth factor protein with pro-angiogenic activity, a forkhead-associated domain, a G-patch domain; characteristic subcellular localization in an in vitro Matrigel model of angiogenesis: towards the cell periphery in early stages of tubulogenesis, between cells in newly formed endothelial tubes, and no nuclear staining after 24 hours; is expressed in endothelial cells; is secreted during angiogenesis; and interacts with TWEAK. The invention also provides for expression vectors containing nucleic acid sequences encoding VG5Q protein, and host cells containing one or more expression vectors for the recombinant expression of VG5Q. The invention also provides for methods of using VG5Q for the diagnosis and treatment of angiogenesis-mediated diseases or disorders. | 2013-03-07 |
20130058941 | MONOCLONAL ANTIBODIES AND BINDING FRAGMENTS THEREOF DIRECTED TO THE MELANOCORTIN-4 RECEPTOR AND THEIR USE IN THE TREATMENT OF CACHEXIA AND RELATED CONDITIONS AND DISEASES - Disclosed are monoclonal antibodies, binding fragments, and derivatives thereof directed to the human melanocortin-4 receptor, as well as pharmaceutical compositions including the same, the therapeutic uses, including methods for treating cachexia and related conditions and diseases, using such monoclonal antibodies, binding fragments, derivatives, and pharmaceutical compositions. | 2013-03-07 |
20130058942 | HUMAN BETA-ADRENERGIC RECEPTOR KINASE POLYPEPTIDE AND METHODS - Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP. | 2013-03-07 |
20130058943 | BOVINE POLYCLONAL ANTIBODY SPECIFIC FOR HUMAN TNF - The invention provides a composition comprising polyclonal antibodies that specifically bind to with human tumor necrosis factor (hTNF) wherein the polyclonal antibodies are derived from the serum, milk or colostrum of a bovine animal that has been immunized hTNF or an immunogenic portion thereof. The antigenic specificity analysis of the anti-hTNF polyclonal antibodies of the invention is unique and has not been previously described for anti-hTNF polyclonal or monoclonal antibodies of the prior art. | 2013-03-07 |
20130058944 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 2013-03-07 |
20130058945 | Antigenic GM-CSF Peptides and Antibodies to GM-CSF - Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease. | 2013-03-07 |
20130058946 | Seizure and Migraine Treatments using Denosumab - A novel pathogenesis underlying certain types of seizures and migraines is disclosed and the validated set of premises presented enable the deductive conclusion to be made that drugs that reduce the amount of calcium ions (Ca++) released from bone reduce seizure and migraine risk. The premises validated as true in the specifications include:
| 2013-03-07 |
20130058947 | Novel Modulators and Methods of Use - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 2013-03-07 |
20130058948 | Antibodies Directed To Gpnmb And Uses Thereof - The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides methods of treating breast cancer using antibodies that bind to GPNMB, immunoconjugates and other derivatives thereof. | 2013-03-07 |
20130058949 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other cogulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al. | 2013-03-07 |
20130058950 | METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF - Diagnostic and therapeutic methods pertaining to diseases and disorders of the breast, uterus and ovary are encompassed herein. More particularly, diagnostic methods for early detection of progenitor cells of breast, uterine, and ovarian cancers are described herein. The identification of markers for these cancer predisposing progenitor cells, which co-express the progesterone receptor (PR) and p63, provides tools and methods of use thereof that facilitate early detection of increased frequency of PR/p63 double positive (PR/p63+) progenitor cells in asymptomatic patients and thus, early detection of increased cancer risk in such patients and assessment, diagnostic stratification, and evaluation of therapeutic intervention in symptomatic patients. Therapeutic methods are also encompassed herein, which include detection of PR/p63+ progenitor cells in a patient, wherein detection of increased frequency of PR/p63+ progenitor cells provides information on which basis a determination of therapeutic regimen or an assessment of an ongoing therapeutic regimen can be made. | 2013-03-07 |
20130058951 | ANTI-S1P ANTIBODY TREATMENT OF PATIENTS WITH OCULAR DISEASE - The present invention relates to methods that involve administration of an anti-S1 P antibody or antibody fragment or derivative to a subject having or suspected of having an ocular disease or condition, including one involving choroidal neovascularization, in order to achieve a desired effect. Such effects include reducing the size of a choroidal neovascularization lesion in the eye, decreasing or resolving retinal pigment epithelial detachment, decreasing central retinal lesion thickness, and preserving or improving visual acuity. Pharmaceutical compositions comprising an anti-S1 P antibody for ocular administration are also provided. The compositions and methods are particularly useful for treating subjects having age-related macular degeneration, particularly exudative or wet age-related macular degeneration. | 2013-03-07 |
20130058952 | ANTI-HSV ANTIBODY - The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims. | 2013-03-07 |
20130058953 | CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation. | 2013-03-07 |
20130058954 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY, KERATOCONUS OR PELLUCID DEGENERATION - The present invention relates to methods of diagnosis and treatment of corneal ectasia following refractive surgery, keratoconus or pellucid marginal degeneration in a subject by determining or modulating the level of expression of molecules associated with the Wnt signalling pathway. Marker molecules of the present invention include SFRP1, PITX2, LEF1, WNT16 and WNT5A. | 2013-03-07 |
20130058955 | ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE - The invention provides anti-polyubiquitin antibodies and methods of using the same. | 2013-03-07 |
20130058956 | EXTRACELLULAR IFI16 AS THERAPEUTIC AGENTS - The present invention relates to the inhibition of the circulating extracellular form of the interferon inducible protein 16 (extracellular IFI16) for the treatment of diseases, particularly autoimmune and/or inflammatory disorders or infective disorders. | 2013-03-07 |
20130058957 | DENDRITIC CELL IMMUNORECEPTOR AGONIST - An object of the present invention is to find a ligand for a DCIR and to search for an agonist and an antagonist for the DCIR. | 2013-03-07 |
20130058958 | COMPOSITIONS AND METHODS USEFUL FOR REDUCING THE VISCOSITY OF PROTEIN-CONTAINING FORMULATIONS - The invention relates to use of certain compounds including, for example, certain charged amino acids and structural analogs thereof, for reducing the viscosity of aqueous protein-containing formulations. Associated compositions of matter and methods of use are also contemplated within the present invention. | 2013-03-07 |
20130058959 | HEMATOPOIETIC CELL SELECTIN LIGAND POLYPEPTIDES AND METHODS OF USE THEREOF - The invention feature methods and compositions for treating inflammatory disorders, hematopoietic disorders and non-hematopoietic disorders (e.g., non-hematopoietic cancers) and for isolating cells (e.g., stem cells) in a mammal. | 2013-03-07 |
20130058960 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 2013-03-07 |
20130058961 | METHOD FOR REDUCING THE THROMBOEMBOLIC POTENTIAL OF A PLASMA-DERIVED IMMUNOGLOBULIN COMPOSITION - The present invention provides methods for reducing the amidolytic and anti-complement activity (ACA) content of an immunoglobulin composition through the use of cation exchange chromatography. In a specific embodiment, the invention provides methods for reducing the Factor XI and/or Factor XIa and/or ACA content of an immunoglobulin composition by collecting the leading portion of a cation exchange eluate. The present invention also provides immunoglobulin composition having reduced levels of amidolytic activity, Factor XI, and/or Factor XIa, and/or ACA content. | 2013-03-07 |
20130058962 | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein - Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant heteromultimeric neutralizing binding protein including two or multiple binding regions, such that the binding regions are not identical, and each binding region specifically binds a non-overlapping portion of the disease agent, thereby treating the subject for exposure to the disease agent. In a related embodiment, the heteromultimeric neutralizing binding protein includes two or multiple binding regions that neutralize a plurality of disease agents. In certain embodiments, the disease agent includes a bacterium, a bacterial protein, a virus, a viral protein, a cancer cell, and a protein or molecule produced therefrom. In certain embodiments, the disease agent is a plurality of different disease agents. | 2013-03-07 |
20130058963 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR GENERATING CD8+ REGULATORY T CELLS - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that generate CD8+ regulatory T cells, as well as related compositions and methods. | 2013-03-07 |
20130058964 | METHODS FOR ACTIVATING T CELLS AND MODULATING AN IMMUNE RESPONSE - The present invention is directed to a method for promoting differentiation, activation and proliferation of human T helper lymphocytes such as those that express IL17 and IL22 (Th-IL17+ and Th-IL22+ T cells) and provides methods for decreasing T cell activation or T cell biological activity, inhibiting an immune response and treating autoimmune diseases by increasing the biological activity of or administering a transcription factor such as a Krüppel-like factor or a forkhead box factor, and pharmaceutical compositions effective for these methods. Also, the present invention provides methods for increasing T cell activation or T cell biological activity, stimulating an immune response and treating diseases such as cancers and infections by decreasing the biological activity of or administering an inhibitor of a transcription factor such as a Krüppel-like factor or a forkhead box factor and pharmaceutical compositions effective for these methods. | 2013-03-07 |
20130058965 | INJECTABLE FORMULATIONS FOR PARENTERAL ADMINISTRATION - Disclosed herein are uses, methods, and processes for preparing or manufacturing a lyophilized cake that comprises a water-insoluble agent, wherein the cake is capable of being disintegrated in a parenterally acceptable solvent to form a syringeable liquid suspension of fine particles of the water-insoluble active agent that is suitable for pharmaceutical uses. Lyophilized cakes prepared according to the methods disclosed herein and kits containing such lyophilized cakes are also disclosed. Further disclosed herein are methods and processes for preparing a syringeable liquid suspension of fine particles of the water-insoluble active agent that is suitable for pharmaceutical uses. | 2013-03-07 |
20130058966 | ANTI-PDEF ANTIBODIES AND USES THEREOF - The present invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds with high affinity to at least a portion of a segment of human prostate-derived Ets transcription factor (PDEF). The anti-PDEF antibody of the present invention is effective in prognostic and diagnostic assays for detecting PDEF with immunohistochemistry. The present invention also relates to methods of making the anti-PDEF antibody disclosed herein. The present invention further relates to vaccines against cancers associated with positive expression of PDEF, as well as methods for treating those cancers. Vectors, diagnostic kits, and hybridomas are also disclosed. | 2013-03-07 |
20130058967 | RECOMBINANT MODIFIED BACILLUS ANTHRACIS PROTECTIVE ANTIGEN FOR USE IN VACCINES - The invention relates to improved methods of producing and recovering sporulation-deficient | 2013-03-07 |
20130058968 | PISCINE REOVIRUS IMMUNOGENIC COMPOSITIONS - The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus poplypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal. | 2013-03-07 |
20130058969 | CHLOROPLASTS ENGINEERED TO EXPRESS PHARMACEUTICAL PROTEINS - Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants. | 2013-03-07 |
20130058970 | INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE SYSTEMIC INFLAMMATORY CYTOKINES - Disclosed are induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods, for reducing systemic inflammatory cytokines. | 2013-03-07 |
20130058971 | INNOCULATION OF RECOMBINANT VIRAL VECTORS FOR RAPID PRE-EXPOSURE PREVENTION AND POST-EXPOSURE PROTECTION AGAINST ALPHAVIRUS-INDUCED ENCEPHALITIDES - This invention addresses how to rapidly prevent alphavirus-induced encephalitides before and after exposure to alphaviruses. The invention discloses a single dose administration of two types of recombinant viral vectors: one expressing interferon and another expressing the structural proteins of alphaviruses or a single dose administration of the recombinant viral vector co-expressing both interferon and the structural proteins of alphaviruses. This invention can be used to prevent humans from alphavirus-induced encephalitides in the event of a bioterrorism attack or biowarfare in which alphaviruses such as Venezuelan (VEEV), eastern (EEEV) and western (WEEV) equine encephalitis viruses are deliberately released to humans, a natural outbreak of alphaviruses, and an accidental exposure to alphaviruses in laboratory. | 2013-03-07 |
20130058972 | METHODS FOR REGULATING COMPLEMENT CASCADE PROTEINS USING ASTROVIRUS COAT PROTEIN AND DERIVATIVES THEREOF - The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives. | 2013-03-07 |
20130058973 | IMMUNE THERAPY - Native Tat, when administered to patients with HIV infection, or who are otherwise immunocompromised, is capable of restoring immune functions so as to recognise recall antigens, and to inhibit replication and key signs of HIV disease and other persistent infections and/or their progression. | 2013-03-07 |
20130058974 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing CD8+ T cell immune responses, as well as related compositions and methods. | 2013-03-07 |
20130058975 | ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE ANTIBODY RESPONSES - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) for reducing undesired humoral immune responses, as well as related compositions and methods. | 2013-03-07 |
20130058976 | ALLERGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS FOR ALLERGY THERAPY - Disclosed are allergen-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 2013-03-07 |
20130058977 | COMPOSITIONS AND METHODS RELATED TO INDUCED TOLEROGENIC DENDRITIC CELLS EXTERNALLY LOADED WITH MHC CLASS I-RESTRICTED EPITOPES - Disclosed are induced tolerogenic dendritic cells (itDCs) produced by combining itDCs with externally loadable MHC Class I-restricted epitopes, as well as related compositions and methods. | 2013-03-07 |
20130058978 | INDUCED TOLEROGENIC DENDRITIC CELLS FOR INDUCING REGULATORY B CELLS - Disclosed are antigen-specific induced tolerogenic dendritic cells (itDCs) that generate regulatory B cells, as well as related compositions and methods. | 2013-03-07 |
20130058979 | TREATMENT AND PREVENTION OF CANCERS ASSOCIATED WITH INTRACELLULAR ONCOPROTEINS BY ANTIBODY THERAPY OR VACCINATION - We provide for the use of an intracellular antibody therapy for targeting intracellular oncoproteins or proteins to prevent cancer metastasis. We also provide for the use of an intracellular vaccine therapy comprising an oncoprotein protein for vaccination to stimulate a host to produce its own antibodies to prevent tumor formation. The antibody may comprise a chimeric antibody. | 2013-03-07 |
20130058980 | SMALL MOLECULE INHIBITORS OF PROTEIN KINASES - Compounds that modulate, for example, that inhibit, syk kinase, and, optionally other kinases. The compounds can be used to treat a variety of disorders, including inflammatory disorders and autoimmune disorders. | 2013-03-07 |
20130058981 | Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia - The present invention relates to combination pharmaceutical compositions comprising an activated-potentiated form of an antibody to endothelial NO synthase and activated potentiated form of an antibody to brain-specific protein S-100 and its use for the treatment of vegetative-vascular dystonia (VVD) and symptoms thereof. | 2013-03-07 |
20130058982 | Method of treating Alzheimer's disease - The present invention relates to a method of treating Alzheimer's disease by administration of activated-potentiated form of antibodies to brain-specific protein S-100 and activated-potentiated form of antibodies to endothelial NO synthase. | 2013-03-07 |